tradingkey.logo

Dyadic International Inc

DYAI

1.070USD

+0.088+9.01%
Close 09/19, 16:00ETQuotes delayed by 15 min
32.25MMarket Cap
LossP/E TTM

Dyadic International Inc

1.070

+0.088+9.01%
More Details of Dyadic International Inc Company
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
Company Info
Ticker SymbolDYAI
Company nameDyadic International Inc
IPO dateNov 05, 2004
CEOMr. Mark A. Emalfarb
Number of employees6
Security typeOrdinary Share
Fiscal year-endNov 05
Address1044 North U.S. Highway One
CityJUPITER
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code33477
Phone15617438333
Websitehttps://dyadic.com/
Ticker SymbolDYAI
IPO dateNov 05, 2004
CEOMr. Mark A. Emalfarb
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Mark A. Emalfarb
Mr. Mark A. Emalfarb
Chief Executive Officer, Director
Chief Executive Officer, Director
4.73M
--
Ms. Ping Wang Rawson, CPA
Ms. Ping Wang Rawson, CPA
Chief Financial Officer
Chief Financial Officer
140.99K
--
Mr. Patrick K. Lucy
Mr. Patrick K. Lucy
Independent Chairman of the Board
Independent Chairman of the Board
50.76K
--
Dr. Ronen Tchelet, Ph.D.
Dr. Ronen Tchelet, Ph.D.
Vice President - Research and Business Development
Vice President - Research and Business Development
32.83K
+37.65%
Dr. Seth J. Herbst, M.D.
Dr. Seth J. Herbst, M.D.
Independent Director
Independent Director
--
--
Mr. Joseph (Joe) Hazelton
Mr. Joseph (Joe) Hazelton
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Mr. Jack L. Kaye, CPA
Mr. Jack L. Kaye, CPA
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Mark A. Emalfarb
Mr. Mark A. Emalfarb
Chief Executive Officer, Director
Chief Executive Officer, Director
4.73M
--
Ms. Ping Wang Rawson, CPA
Ms. Ping Wang Rawson, CPA
Chief Financial Officer
Chief Financial Officer
140.99K
--
Mr. Patrick K. Lucy
Mr. Patrick K. Lucy
Independent Chairman of the Board
Independent Chairman of the Board
50.76K
--
Dr. Ronen Tchelet, Ph.D.
Dr. Ronen Tchelet, Ph.D.
Vice President - Research and Business Development
Vice President - Research and Business Development
32.83K
+37.65%
Dr. Seth J. Herbst, M.D.
Dr. Seth J. Herbst, M.D.
Independent Director
Independent Director
--
--
Mr. Joseph (Joe) Hazelton
Mr. Joseph (Joe) Hazelton
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jun 25
Updated: Wed, Jun 25
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Emalfarb (Mark A)
13.07%
Francisco Trust
9.42%
Bandera Partners LLC
3.82%
Chapin Davis Asset Management
2.44%
The Vanguard Group, Inc.
2.38%
Other
68.86%
Shareholders
Shareholders
Proportion
Emalfarb (Mark A)
13.07%
Francisco Trust
9.42%
Bandera Partners LLC
3.82%
Chapin Davis Asset Management
2.44%
The Vanguard Group, Inc.
2.38%
Other
68.86%
Shareholder Types
Shareholders
Proportion
Individual Investor
15.84%
Corporation
9.42%
Investment Advisor
8.08%
Investment Advisor/Hedge Fund
4.86%
Bank and Trust
0.72%
Hedge Fund
0.15%
Venture Capital
0.05%
Research Firm
0.01%
Other
60.85%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
72
14.22M
39.41%
-66.96K
2025Q1
74
14.15M
47.29%
-44.89K
2024Q4
76
13.93M
47.30%
-33.37K
2024Q3
75
13.71M
46.92%
-360.61K
2024Q2
74
13.61M
46.61%
-301.69K
2024Q1
70
13.58M
46.69%
+53.57K
2023Q4
68
13.19M
45.91%
-223.07K
2023Q3
76
13.18M
46.01%
-549.63K
2023Q2
90
13.18M
46.01%
-1.13M
2023Q1
118
13.17M
45.97%
-1.38M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Emalfarb (Mark A)
4.73M
15.72%
--
--
Apr 24, 2025
Francisco Trust
3.41M
11.33%
--
--
Apr 24, 2025
Bandera Partners LLC
1.57M
5.21%
--
--
Mar 31, 2025
Chapin Davis Asset Management
842.85K
2.8%
-25.45K
-2.93%
Mar 31, 2025
The Vanguard Group, Inc.
814.34K
2.71%
+8.54K
+1.06%
Mar 31, 2025
Tarnok (Michael P)
281.03K
0.93%
+10.78K
+3.99%
Jun 20, 2025
Geode Capital Management, L.L.C.
258.42K
0.86%
+18.25K
+7.60%
Mar 31, 2025
Northeast Financial Consultants Inc
250.00K
0.83%
--
--
Mar 31, 2025
Truist Bank
250.00K
0.83%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
246.86K
0.82%
-969.00
-0.39%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI